Objective: To review the efficacy and safety of fesoterodine, a new antimuscarinic for treating overactive bladder (OAB) symptoms. Methods: Review of efficacy and safety data from the pivotal phase 3 ...

—Maybe, say the results of a UK meta-analysis, which found some patients to benefit from the alternative approach. Considering the side effects of certain OAB medications and poor adherence, it’s ...

Watch Virginia This Morning each weekday from 9 to 10 a.m. Find the show on Facebook and Instagram at @VirginiaThisMorning.

Standard stepwise therapy for overactive bladder (OAB) begins with conservative therapies such as lifestyle interventions and behavioral approaches. Medications—anticholinergics or beta-3 agonists—are ...

The approval was based on data from the pivotal phase 3 EMPOWUR study. The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron; Urovant Sciences) for the treatment of overactive ...

Please provide your email address to receive an email when new articles are posted on . Results from the EMPOWUR extension study presented at the virtual International Continence Society Annual ...

Q: In two weeks, I am supposed to get Botox injections in my bladder for an overactive bladder (OAB) and my frequent need to urinate at nighttime. Are these injections safe? Are there any bad side ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

Gemtesa is an oral, once-daily, small molecule beta-3 adrenergic agonist. Gemtesa ® (vibegron; Urovant Sciences) is now available for the treatment of overactive bladder (OAB) with symptoms of urge ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The novel muscarinic M3 receptor ...

An error has occurred. Please try again. With a Lewiston Sun Journal subscription, you can gift 5 articles each month. It looks like you do not have any active ...